close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

3.800 +0.140 (+3.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atai Beckley N.V - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration 
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
News headline image
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
atai Life Sciences Awarded Grant from the National Institutes of Health
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 
From atai Life Sciences
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in Upcoming Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
Via Investor Brand Network
News headline image
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today